TY - JOUR
T1 - IPS cell technologies
T2 - Significance and applications to CNS regeneration and disease
AU - Okano, Hideyuki
AU - Yamanaka, Shinya
N1 - Funding Information:
We thank all of the members of the Okano and Yamanaka laboratories for their encouragement and support. We are also grateful to Dr. Masaya Nakamura for providing a prototype graphic for Figure 3 and Prof. Ole Isacson at Harvard Medical School for valuable discussions. This study was supported by grants from the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells funded by the Japan Science and Technology Agency (JST) to H.O. and S.Y.
PY - 2014/3/31
Y1 - 2014/3/31
N2 - In 2006, we demonstrated that mature somatic cells can be reprogrammed to a pluripotent state by gene transfer, generating induced pluripotent stem (iPS) cells. Since that time, there has been an enormous increase in interest regarding the application of iPS cell technologies to medical science, in particular for regenerative medicine and human disease modeling. In this review article, we outline the current status of applications of iPS technology to cell therapies (particularly for spinal cord injury), as well as neurological disease-specific iPS cell research (particularly for Parkinson's disease and Alzheimer's disease). Finally, future directions of iPS cell research are discussed including a) development of an accurate assay system for disease-associated phenotypes, b) demonstration of causative relationships between genotypes and phenotypes by genome editing, c) application to sporadic and common diseases, and d) application to preemptive medicine.
AB - In 2006, we demonstrated that mature somatic cells can be reprogrammed to a pluripotent state by gene transfer, generating induced pluripotent stem (iPS) cells. Since that time, there has been an enormous increase in interest regarding the application of iPS cell technologies to medical science, in particular for regenerative medicine and human disease modeling. In this review article, we outline the current status of applications of iPS technology to cell therapies (particularly for spinal cord injury), as well as neurological disease-specific iPS cell research (particularly for Parkinson's disease and Alzheimer's disease). Finally, future directions of iPS cell research are discussed including a) development of an accurate assay system for disease-associated phenotypes, b) demonstration of causative relationships between genotypes and phenotypes by genome editing, c) application to sporadic and common diseases, and d) application to preemptive medicine.
KW - Alzheimer's disease
KW - Cell transplantation
KW - Induced pluripotent stem cell
KW - Modeling human diseases
KW - Parkinson's disease
KW - Spinal cord injury
UR - http://www.scopus.com/inward/record.url?scp=84898464540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898464540&partnerID=8YFLogxK
U2 - 10.1186/1756-6606-7-22
DO - 10.1186/1756-6606-7-22
M3 - Article
C2 - 24685317
AN - SCOPUS:84898464540
SN - 1756-6606
VL - 7
JO - Molecular Brain
JF - Molecular Brain
IS - 1
M1 - 22
ER -
